Wedbush Research Analysts Lower Earnings Estimates for APGE

Apogee Therapeutics, Inc. (NASDAQ:APGE) – Investment analysts at Wedbush cut their Q1 2025 earnings per share (EPS) estimates for Apogee Therapeutics in a research note issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.24) per share for the quarter, down from their previous forecast of ($0.99). Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics’ Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($5.07) EPS, FY2027 earnings at ($5.56) EPS and FY2028 earnings at ($7.00) EPS.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group began coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Canaccord Genuity Group began coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Finally, Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $88.83.

Apogee Therapeutics Stock Up 3.5 %

Shares of Apogee Therapeutics stock opened at $31.43 on Thursday. Apogee Therapeutics has a 12-month low of $29.10 and a 12-month high of $72.29. The firm has a market capitalization of $1.42 billion, a PE ratio of -12.99 and a beta of 2.46. The stock’s fifty day moving average is $39.67 and its 200-day moving average is $47.21.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.25).

Insider Buying and Selling

In other news, Director Mark C. Mckenna purchased 20,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $49.54 per share, with a total value of $990,800.00. Following the purchase, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $990,800. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Carl Dambkowski sold 3,520 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total value of $143,228.80. Following the sale, the insider now directly owns 252,623 shares of the company’s stock, valued at $10,279,229.87. This trade represents a 1.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,145 shares of company stock valued at $1,897,799. Corporate insiders own 36.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Apogee Therapeutics during the 4th quarter valued at about $43,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Apogee Therapeutics in the 3rd quarter valued at approximately $71,000. Wexford Capital LP acquired a new stake in Apogee Therapeutics in the 3rd quarter valued at approximately $230,000. Optimize Financial Inc acquired a new stake in Apogee Therapeutics in the 4th quarter valued at approximately $203,000. Finally, Aigen Investment Management LP acquired a new stake in Apogee Therapeutics in the 4th quarter valued at approximately $216,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.